Sugi Predict

Sugi Predict / Compounds / SCHEMBL6733333

SCHEMBL6733333

SCHEMBL6733333

CS(=O)(=O)c1cc(F)c(-c2nc(C(F)F)[nH]c2-c2cccc(Cl)c2)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TYK2 P29597 3/20 0.36
▸ SCD O00767 1/20 0.36
▸ ATM Q13315 1/20 0.35
▸ PTGS2 P35354 2/20 0.34
▸ TGFBR1 P36897 2/20 0.34
▸ TGFBR2 P37173 2/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ NR1H3 Q13133 1/20 0.34
▸ PIN1 Q13526 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ SLC9A1 P19634 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ NR3C1 P04150 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ NR3C2 P08235 1/20 0.33
▸ AR P10275 1/20 0.33
▸ MAPK13 O15264 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733537 0.91 TYK2 (0.33) TYK2PTGS2ALOX5
SCHEMBL6736125 0.90 SCD (0.37) TYK2SCDPTGS2NR1H2NR1H3
SCHEMBL6732500 0.89 MAPK14 (0.39) RAB9APTGS2NR1H2NR1H3PIN1
SCHEMBL6736934 0.89 PTGS2 (0.42) TYK2PTGS2ALOX5MAPK13MAPK12
SCHEMBL6739660 0.88 ALDH1A1 (0.43) PTGS2NR1H2NR1H3ALOX5MAPK14
SCHEMBL6734086 0.88 MAPK13 (0.35) TYK2PTGS2NR1H2NR1H3ALOX5
SCHEMBL6732359 0.87 ALOX5 (0.35) KMT2APTGS2ALOX5MAPK14
SCHEMBL6732424 0.87 SCN9A (0.38) TYK2PTGS2SCN9AALOX5
SCHEMBL6722954 0.87 TGFBR1 (0.41) IDO1RAB9AKMT2ATYK2SCD
SCHEMBL6728226 0.86 MAPK14 (0.40) KMT2ATYK2PTGS2NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 — — US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 — — US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 — — US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 — — US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 IDO1 183/4885RAB9A 4116/4885KMT2A 3180/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 IDO1 183/4885RAB9A 4116/4885KMT2A 3180/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 IDO1 183/4885RAB9A 4116/4885KMT2A 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.